View in EDS

Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Saved in:

Bibliographic Details
Title:	Therapeutic potential of ERK5 targeting in triple negative breast cancer.
Authors:	Ortiz-Ruiz MJ; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain., Álvarez-Fernández S; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain., Parrott T; Tragara Pharmaceuticals, Carlsbad, CA, USA., Zaknoen S; Tragara Pharmaceuticals, Carlsbad, CA, USA., Burrows FJ; Tragara Pharmaceuticals, Carlsbad, CA, USA., Ocaña A; Hospital Universitario de Albacete, and AECC Unit, Spain., Pandiella A; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain., Esparís-Ogando A; Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL-Universidad de Salamanca. Spain.
Source:	Oncotarget [Oncotarget] 2014 Nov 30; Vol. 5 (22), pp. 11308-18.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1949-2553
DOI:	10.18632/oncotarget.2324